Dendritic Cell News and Research

Latest Dendritic Cell News and Research

Cluster signaling mechanism causes T cells to turn pathogenic in multiple sclerosis, research shows

Multiple sclerosis is an autoimmune disease in which the body's immune system attacks the patient's own cells.

1 Dec 2016

New discovery helps explain why HIV infection increases risk for active tuberculosis

The HIV virus increases the potency of the tuberculosis bacterium (Mtb) by affecting a central function of the immune system.

18 Oct 2016

UCLA researchers develop new combination therapy to activate immune response against glioblastoma

UCLA researchers have developed a new breakthrough combination treatment that utilizes a vaccine to activate an immune response against advanced brain tumors.

8 Jul 2016

Group of gamma-protocadherins linked with neurons help regulate growth of dendrites

When you think of a neuron, imagine a tree. A healthy brain cell indeed looks like a tree with a full canopy. There's a trunk, which is the cell's nucleus; there's a root system, embodied in a single axon; and there are the branches, called dendrites.

28 Apr 2016

Naturally-occurring molecule can cause immune cells to go into hyperactive state

Researchers at Boston Children's Hospital report that a fatty chemical naturally found in damaged tissues can induce an unexpected kind of immune response, causing immune cells to go into a "hyperactive" state that is highly effective at rallying infection-fighting T-cells. The findings, published online by Science on April 21, could enhance vaccines and make them much more effective.

22 Apr 2016

Asterias announces successful completion of End-of-Phase 2 meeting with FDA for AML therapy

Asterias Biotherapeutics, Inc. today announced the successful completion of an End-of-Phase 2 meeting with the U.S. Food and Drug Administration for AST-VAC1, its investigational therapy targeting acute myeloid leukemia (AML).

24 Feb 2016

New optogenetic technology could turn on immune cells to attack melanoma tumors

A new optogenetic technology developed at UMass Medical School, called optogenetic immunomodulation, is capable of turning on immune cells to attack melanoma tumors in mice. Using near-infrared light, UMMS researchers have shown they can selectively activate an immune response by controlling the flow of calcium ions into the cell. This breakthrough could lead to less invasive, and more controlled and selective, immunotherapies for cancer treatment.

17 Feb 2016

Asterias Biotherapeutics simplifies capital structure through previously announced Asset Swap with BioTime

Asterias Biotherapeutics, Inc., a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today simplified its capital structure through the previously announced Asset Swap with BioTime, Inc.

17 Feb 2016

Researchers explore ways to use light to combat cancer

Immunotherapy is one of the hottest emerging areas of cancer research. After all, using the body's own cells to fight cancer can be more effective and less invasive than flooding the entire system with toxic chemicals.

22 Jan 2016

Northwest Biotherapeutics closes registered direct placement of $12.6M

Northwest Biotherapeutics, a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced the closing of its previously-announced registered direct placement with healthcare focused institutional investors, for gross proceeds of $12.6 million on the terms previously announced.

26 Dec 2015

ImmunoCellular partners with CBTC for ICT-107 phase 3 registrational trial in patients with glioblastoma

ImmunoCellular Therapeutics, Ltd. today announced the establishment of an agreement with a major Canadian cancer cooperative group, The Canadian Brain Tumour Consortium, for the phase 3 registrational trial of its cancer immunotherapy ICT-107 in patients with newly diagnosed glioblastoma.

14 Dec 2015

Asterias’ Phase 1/2a study evaluates dose escalation of AST-OPC1 for cervical spinal cord injury

Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, today announced that its Data Monitoring Committee has reviewed the initial safety data from all three patients in the first cohort and has recommended dose escalation to the second cohort.

20 Oct 2015

Mysteries of neurological disorders being revealed by research scientists

Zeiss LSM 780 laser scanning microscope provides high resolution and fast imaging for studies on neuronal structure, function, and neuro development.

16 Sep 2015

Three medical oncologists to receive ESMO's acclaimed awards

The European Society for Medical Oncology, the leading European professional organisation for advancing medical oncology, announced today the three exceptional medical oncologists who will receive its acclaimed awards.

24 Aug 2015

NW Bio's DCVax-L Phase III trial ongoing for treatment of patients with newly diagnosed GBM

Northwest Biotherapeutics, a U.S. biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, confirmed today that its Phase III trial of DCVax-L for newly diagnosed glioblastoma multiforme (GBM) is ongoing and the patients enrolled in the trial are continuing to be treated per the protocol.

23 Aug 2015

Study sheds light on helper cells and killer cells

Scientists at the University of Bonn, together with colleagues from the USA and Japan, have shed light on an important immune mechanism. Their work shows how the body provides the important killer cells with a helper in the case of an infection. The study could point the way to better vaccines in the future.

21 Aug 2015

ImmunoCellular signs agreement with FDA for phase 3 registrational trial of cancer immunotherapy ICT-107

ImmunoCellular Therapeutics, Ltd. announced today that it has reached agreement with the US Food and Drug Administration on a Special Protocol Assessment (SPA) for the phase 3 registrational trial of its cancer immunotherapy ICT-107 to treat patients with newly diagnosed glioblastoma.

13 Aug 2015

Argos Therapeutics begins AGS-003 clinical trial in patients with metastatic renal cell carcinoma

Argos Therapeutics Inc., an immuno-oncology company focused on the development and commercialization of fully individualized immunotherapies for the treatment of cancer based on the Arcelis technology platform, today announced the initiation of a single-center pilot clinical trial of AGS-003 as a neoadjuvant immunotherapy in patients with localized renal cell carcinoma.

11 Aug 2015

CRI to honor three scientists for contributions to immunology and cancer immunotherapy research

The Cancer Research Institute, a nonprofit organization dedicated to fueling the discovery and development of immunotherapies for all forms of cancer, will bestow its highest honors on three scientists who have made fundamental contributions to the fields of immunology and cancer immunotherapy.

10 Aug 2015

ImmunoCellular, Novella partner to conduct ICT-107 phase 3 registration trial in patients with glioblastoma

ImmunoCellular Therapeutics, Ltd. today announced the establishment of an agreement with Novella Clinical (Novella), to conduct the phase 3 registration trial of ICT-107 in patients with newly diagnosed glioblastoma. Novella is a full-service, global clinical research organization (CRO) providing clinical trial services to small to mid-sized oncology companies.

6 Jul 2015

Dendritic Cell News and Research

Latest Dendritic Cell News and Research

Cluster signaling mechanism causes T cells to turn pathogenic in multiple sclerosis, research shows

New discovery helps explain why HIV infection increases risk for active tuberculosis

UCLA researchers develop new combination therapy to activate immune response against glioblastoma

Group of gamma-protocadherins linked with neurons help regulate growth of dendrites

Naturally-occurring molecule can cause immune cells to go into hyperactive state

Asterias announces successful completion of End-of-Phase 2 meeting with FDA for AML therapy

New optogenetic technology could turn on immune cells to attack melanoma tumors

Asterias Biotherapeutics simplifies capital structure through previously announced Asset Swap with BioTime

Researchers explore ways to use light to combat cancer

Northwest Biotherapeutics closes registered direct placement of $12.6M

ImmunoCellular partners with CBTC for ICT-107 phase 3 registrational trial in patients with glioblastoma

Asterias’ Phase 1/2a study evaluates dose escalation of AST-OPC1 for cervical spinal cord injury

Mysteries of neurological disorders being revealed by research scientists

Three medical oncologists to receive ESMO's acclaimed awards

NW Bio's DCVax-L Phase III trial ongoing for treatment of patients with newly diagnosed GBM

Study sheds light on helper cells and killer cells

ImmunoCellular signs agreement with FDA for phase 3 registrational trial of cancer immunotherapy ICT-107

Argos Therapeutics begins AGS-003 clinical trial in patients with metastatic renal cell carcinoma

CRI to honor three scientists for contributions to immunology and cancer immunotherapy research

ImmunoCellular, Novella partner to conduct ICT-107 phase 3 registration trial in patients with glioblastoma

Immunology eBook

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Dendritic Cell News and Research

Latest Dendritic Cell News and Research

Immunology eBook

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in